Anadol Remzi, Dimitriadis Zisis, Polimeni Alberto, Wendling Franziska, Gönner Svenja, Ullrich Helen, Lorenz Liv, Weissner Melissa, Munzel Thomas, Gori Tommaso
Kardiologie I, Universitätsmedizin Mainz und DZHK Standort Rhein-Main, Mainz, Germany.
Clin Hemorheol Microcirc. 2018;69(1-2):3-8. doi: 10.3233/CH-189101.
To investigate three-year outcomes of patients presenting with nonSTelevation acute coronary syndrome (NSTE-ACS) treated with bioresorbable everolimus-eluting vascular scaffolds (BRS).
The study included a total of 488 consecutive patients, enrolled between May 2012 and December 2013 (median age 65 [56-74], 392 men. 269 patients presented with either NSTEMI or unstable angina at the time of enrolling, 219 patients with stable or silent angina. The primary device-oriented endpoint (Target Lesion Failure, TLF) was defined as a combination of cardiovascular death, target vessel myocardial infarction or clinically driven target lesion revascularization.Among the cardiac risk factors, NSTE-ACS patients were more frequently smokers (P = 0.028), had less frequently dyslipidemia (P = 0.003) and a history of prior PCI (P < 0.01).The median follow-up was 1070[763-1197] days. The three-years incidence of TLF was slightly higher but did not differ significantly between groups (NSTE-ACS: 16.3% vs. 15.9%, p = 0.163). Accordingly, there was no difference in any of the other endpoints.
Treatment of NSTE-ACS with BRS appears to be safe and effective. In this group, risk factors for events during follow up did not differ as compared to the general population.
研究使用生物可吸收依维莫司洗脱血管支架（BRS）治疗的非ST段抬高型急性冠状动脉综合征（NSTE-ACS）患者的三年预后。
该研究共纳入488例连续患者，于2012年5月至2013年12月期间入组（中位年龄65岁[56 - 74岁]，男性392例）。269例患者在入组时表现为非ST段抬高型心肌梗死（NSTEMI）或不稳定型心绞痛，219例患者表现为稳定型或无症状型心绞痛。主要的以器械为导向的终点（靶病变失败，TLF）定义为心血管死亡、靶血管心肌梗死或临床驱动的靶病变血运重建的组合。在心脏危险因素中，NSTE-ACS患者吸烟更频繁（P = 0.028），血脂异常较少见（P = 0.003），且既往有经皮冠状动脉介入治疗（PCI）史较少（P < 0.01）。中位随访时间为1070天[763 - 1197天]。TLF的三年发生率略高，但两组间无显著差异（NSTE-ACS组：16.3% vs. 15.9%，p = 0.163）。因此，其他任何终点均无差异。
使用BRS治疗NSTE-ACS似乎是安全有效的。在该组中，随访期间事件的危险因素与一般人群相比无差异。
